Infinity Pharmaceuticals Inc: Premium Company Profile
Scope
Report Highlights
Reasons to Purchase
Table of Contents
- Overview - page 1
- Catalyst - page 1
- Summary - page 1
- Table of Contents - page 3
- Table of figures - page 4
- Table of tables - page 5
- Company Structure - page 6
- Company Overview and Key Facts - page 6
- Business Description - page 7
- Landmark Products & Services - page 8
- Synthesis chemistry technology - page 8
- Landmark Products & Services - page 8
- History - page 9
- M&A History - page 10
- Discovery Partners International - page 10
- M&A History - page 10
- Company Financials - page 11
- Stock Market Performance - page 11
- P&L - page 12
- Balance Sheet - page 15
- Cash Flow - page 15
- Business Segment Performance - page 16
- Products & Services - page 17
- Pipeline Products - page 17
- Collaboration Pipeline - page 17
- IPI-504 - page 17
- Hedgehog Pathway Inhibitors - page 18
- Bcl Family Proteins - page 18
- Collaboration Pipeline - page 17
- AC Forecast Product Sales - page 19
- Pipeline Products - page 17
- Competitors and Strategic Business Relationships - page 20
- Top Competitors - page 20
- Key Clients - page 20
- Shareholding Structure - page 22
- Strategy - page 23
- Company View - page 23
- Corporate Strategy - page 25
- SWOT Analysis - page 27
- Overview - page 27
- Strengths - page 28
- Strategic alliances - page 28
- Synthesis chemistry technology - page 28
- Weaknesses - page 29
- Early stage pipeline - page 29
- Opportunities - page 30
- Merger with Discovery Partners International - page 30
- IPI-504 - page 30
- Threats - page 31
- Industry consolidation - page 31
- Value Chain Analysis - page 32
- Overview - page 32
- Discovery and Product Development - page 32
- Scorecard - page 33
- Overview - page 33
- Scorecard Analysis - page 34
- Key Employees - page 35
- List of Key Employees - page 35
- Key Employee Biographies - page 36
- Steven H. Holtzman - page 36
- D. Ronald Daniel - page 36
- Anthony B. Evnin - page 37
- Harry Hixson - page 37
- Eric S. Lander - page 38
- Patrick Lee - page 38
- Arnold J. Levine - page 39
- Frank Moss - page 39
- Herm Rosenman - page 40
- Vicki L. Sato - page 40
- James B. Tananbaum - page 41
- Michael C. Venuti - page 41
- Julian Adams - page 42
- David S. Grayzel - page 42
- Steven J. Kafka - page 43
- Vito J. Palombella - page 43
- Adelene Q. Perkins - page 44
- Gerald E. Quirk - page 44
- Jeffrey K. Tong - page 45
- James L. Wright - page 45
- Financial and Operational Overview - page 46
- Financial and Operational Overview - page 46
- Appendix - page 48
- Ask the analyst - page 48
- Datamonitor consulting - page 48
- Disclaimer - page 48
- List of Tables
- Table 1: Infinity - Key Facts - page 6
- Table 2: Infinity - Year-End Share Price and Market Capitalization, 2002-2006 ($) - page 11
- Table 3: Infinity - Key Events Impacting Share Price Performance - page 11
- Table 4: Infinity - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) - page 12
- Table 5: Infinity - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) - page 13
- Table 6: Infinity - Balance Sheet, 2002-2006 ($ Mn) - page 15
- Table 7: Infinity - Cash Flow, 2002-2006 ($ Mn) - page 15
- Table 8: Infinity - Revenue Breakdown, 2002-2006 ($ Mn) - page 16
- Table 9: Infinity - Collaboration Pipeline Products - page 17
- Table 10: Infinity - Forecast Sales, 2006-2010 ($ Mn) - page 19
- Table 11: Infinity - Top Competitors - page 20
- Table 12: Infinity - Key Clients - page 21
- Table 13: Infinity - Key Shareholders - page 22
- Table 14: Infinity - SWOT Analysis Summary - page 27
- Table 15: Infinity - Value Chain Analysis - page 32
- Table 16: Infinity - Scorecard - page 33
- Table 17: Infinity - Key Employees - page 35
- Table 18: Infinity - Financial and Operational Overview - page 46
- List of Figures
- Figure 1: Infinity - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) - page 13
Other users found this report page using the following search terms: infinity pharmaceuticals inc pharmaceutical email up ron development competitors set
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.